Terms: = Pancreatic cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Clinical Outcome
4 results:
1. A crucial epithelial to mesenchymal transition regulator, Sox4/ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients.
Hasegawa S; Nagano H; Konno M; Eguchi H; Tomokuni A; Tomimaru Y; Asaoka T; Wada H; Hama N; Kawamoto K; Marubashi S; Nishida N; Koseki J; Mori M; Doki Y; Ishii H
Int J Oncol; 2016 Jan; 48(1):145-52. PubMed ID: 26648239
[TBL] [Abstract] [Full Text] [Related]
2. A polymorphism in the promoter is associated with ezh2 expression but not with outcome in advanced pancreatic cancer patients.
Maftouh M; Avan A; Funel N; Paolicchi E; Vasile E; Pacetti P; Vaccaro V; Faviana P; Campani D; Caponi S; Mambrini A; Boggi U; Cantore M; Milella M; Peters GJ; Reni M; Giovannetti E
Pharmacogenomics; 2014 Apr; 15(5):609-18. PubMed ID: 24798718
[TBL] [Abstract] [Full Text] [Related]
3. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer.
Bao B; Ali S; Ahmad A; Li Y; Banerjee S; Kong D; Aboukameel A; Mohammad R; Van Buren E; Azmi AS; Sarkar FH
Stem Cells Dev; 2014 Aug; 23(16):1947-58. PubMed ID: 24734907
[TBL] [Abstract] [Full Text] [Related]
4. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]
